Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 19, 2017
What is the competitive landscape for HORIZON PHARMA, and what generic alternatives to HORIZON PHARMA drugs are available?
HORIZON PHARMA has eight approved drugs.| Patents: | 53 |
| Tradenames: | 7 |
| Ingredients: | 7 |
| NDAs: | 8 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
diclofenac sodium | Topical Solution | 2.0% | PENNSAID | 6/3/2014 |
prednisone | Delayed-release Tablets | 1 mg, 2 mg, and 5 mg | RAYOS | 11/26/2012 |
diclofenac sodium | Topical Solution | 1.5% | PENNSAID | 7/11/2012 |
ibuprofen and famotidine | Tablets | 800 mg/26.6 mg | DUEXIS | 12/6/2011 |
naproxen and esomeprazole magnesium | Delayed-release Tablet | 375 mg/20 mg and 500 mg/20 mg | VIMOVO | 11/5/2010 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8,129,433 | Enterically coated cysteamine, cystamine and derivatives thereof | ► Subscribe | |||||||||||||||||||||||||||
| 6,677,455 | Potassium salt of S-omeprazole | ► Subscribe | |||||||||||||||||||||||||||
| 8,206,741 | Pharmaceutical compositions for the coordinated delivery of NSAIDs | ► Subscribe | |||||||||||||||||||||||||||
| 8,466,175 | Form of S-omeprazole | ► Subscribe | |||||||||||||||||||||||||||
| 8,920,838 | Delayed-release glucocorticoid treatment of rheumatoid disease | ► Subscribe | |||||||||||||||||||||||||||
| 8,076,361 | Form of S-omeprazole | ► Subscribe | |||||||||||||||||||||||||||
| 9,511,039 | Enterically coated cysteamine, cystamine and derivatives thereof | ► Subscribe | |||||||||||||||||||||||||||
| 6,747,155 | Process | ► Subscribe | |||||||||||||||||||||||||||
| 9,364,439 | Pharmaceutical compositions for the coordinated delivery of NSAIDs | ► Subscribe | |||||||||||||||||||||||||||
| 8,865,190 | Pharmaceutical compositions for the coordinated delivery of NSAIDs | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Canada | 2764963 | ► Subscribe | |||||||||||||||||||||||||||
| Morocco | 32692 | ► Subscribe | |||||||||||||||||||||||||||
| World Intellectual Property Organization (WIPO) | 0224206 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 2002105072 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 2009545546 | ► Subscribe | |||||||||||||||||||||||||||
| Australia | 2010263304 | ► Subscribe | |||||||||||||||||||||||||||
| Canada | 2736547 | ► Subscribe | |||||||||||||||||||||||||||
| Denmark | 1919458 | ► Subscribe | |||||||||||||||||||||||||||
| Israel | 159129 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 2002501529 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2011005,C0984957 | Lithuania | ► Subscribe | PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126 | ||||||||||||||||||||||||||
| C/GB98/040 | United Kingdom | ► Subscribe | PRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508 | ||||||||||||||||||||||||||
| C/GB11/013 | United Kingdom | ► Subscribe | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 | ||||||||||||||||||||||||||
| 00481 | Netherlands | ► Subscribe | PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17901/0263-001 20101105 | ||||||||||||||||||||||||||
| C/GB08/036 | United Kingdom | ► Subscribe | PRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425 | ||||||||||||||||||||||||||
| 2012 00036 | Denmark | ► Subscribe | |||||||||||||||||||||||||||
| C/GB07/011 | United Kingdom | ► Subscribe | PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003 | ||||||||||||||||||||||||||
| 2012000051 | Germany | ► Subscribe | PRODUCT NAME: KOMBINATIONSPRODUKT UMFASSEND NAPROXEN UND ESOMEPRAZOL-MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105 | ||||||||||||||||||||||||||
| C/GB98/025 | United Kingdom | ► Subscribe | PRODUCT NAME: MONTELUKAST, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREFERABLY MONTELUKAST SODIUM; REGISTERED: FI 12766 19970825; FI 12767 19970825; UK 00025/0357 19980115; UK 00025/0358 19980115 | ||||||||||||||||||||||||||
| /2014 | Austria | ► Subscribe | PRODUCT NAME: CYSTEAMIN; REGISTRATION NO/DATE: EU/1/13/861/001-002 20130910 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,665 others who get our Drug Patent Expiration Alerts:
